Table 3.

Duration of CR for adults receiving tipifarnib following two-cycle timed sequential therapy: comparison with two-cycle timed sequential therapy without subsequent maintenance therapy

	Two-cycle TST plus tipifarnib	Two-cycle TST unmaintained	HR (P)
CR duration [median (range)], mo
All patients	14.5 (3.5–59+)	10 (3–60+)	0.68 (0.26)
Age ≥60 y	10.2 (3.5–51+)	7.7 (4–60+)	0.73 (0.50)
Secondary AML	14.5 (5.2–59+)	8.7 (3–60+)	0.28 (0.01)
Adverse cytogenetics	16 (5.1–59+)	8.3 (3–60+)	0.42 (0.07)
DFS ≥12 mo, n (%)
All patients	14/25 (56)	7/23 (30)
Age ≥60 y	5/13 (38)	3/13 (19)
Secondary AML	7/12 (58)	2/12 (17)
Adverse cytogenetics	9/15 (60)	4/14 (29)

Abbreviation: TST, timed sequential therapy.